Stem Cell Manufacturing Market Size, DROT, Porter s, PEST, Region & Country Revenue Analysis & Forecast Till 2028
iCrowd Newswire
06 Jul 2021, 09:08 GMT+10
Major factors driving market revenue growth include increasing use of stem cells to treat various diseases, increasing stem cell-based research activities, and growing funding in stem cell-based research.
Market Size – USD 17.05 Billion in 2020 Market Growth – 6.8% Market Trends – Technological advancements in cell therapy and increasing emphasis on development of personalized medicines
The global stem cell manufacturing market size is expected to reach USD 28.85 billion by 2028, registering a CAGR of 6.8% over the forecast period, according to the latest report by Reports and Data.Major factors driving market revenue growth include increasing use of stem cells to treat various diseases, growing stem cell-based research activities and rising funding from in stem cell-based research. Market growth is being aided by techn
Cathie Wood Buys Another $9.6M In Uipath, Raises Stake In Automation Company To $670M
UiPath Inc (NYSE:PATH).
Shares of the New York-based software automation company closed 1.04% higher at $69.77 on Friday.
The investment firm made the purchase via the
Ark
Genomic Revolution ETF (BATS:ARKG).
Ark owns PATH shares via all of its six active ETFs. On a consolidated basis, the Wood-led firm now holds over 10 million shares, worth around $670 million in UiPath.
The products of the Bucharest, Romania-based software company are used by organizations to help efficiently automate their various business processes. PATH closed 5.34% higher on Wednesday, giving the company a market valuation of $35.8 billion.
Biodefense Market is expected to reachUS$ 8,350.74 Mn by 2027 with Bavarian Nordic, Alnylam Pharmaceuticals, Inc., SIGA Technologies, Emergent BioSolutions
Israeli biotech leadercalls for Arab-Jewish coexistence
A letter from the CEO of Pluristem to multiethnic staff urging love and acceptance has gone viral as people all over the world find strength and comfort in his words.
A hope for peace in Israel. Photo of the Western Wall, by Shutterstock
“Tell your friends on the phone, on the internet, about your Jewish friend that you really love, tell your friends about the Arab friend who works with you on the team,” the CEO &President of an Israeli biotech company urged his staff this week in an email.
“[Tell them] that you live together, eat together and dream together. Tell about your employees, your managers, your friends. Tell our story.”
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Pluristem reports positive topline Phase I results in innovative hematology program, which is .
Pluristem Therapeutics, Inc.April 29, 2021 GMT
New therapy has potential to generate improved blood counts in all three blood cell lineages, a meaningful advantage over existing treatments
The company will conduct an analyst and investor call on May 3, 2021, at 10am EDT
HAIFA, Israel, April 29, 2021 (GLOBE NEWSWIRE) Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE: PSTI), a leading regenerative medicine company, today reported positive topline results in its first study to evaluate the safety and exploratory efficacy of PLX-R18 in humans. The company’s Phase I, open-label, dose-escalation study is evaluating the safety and exploratory efficacy of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT).